Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma levels of CDP-1 in vancomycin-treated patients with different renal function
2015-005349-29Phase 4Terminated
- Sponsor
- Xellia Pharmaceuticals
- Start
- Apr 2016
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin (2 cohorts), sponsored by Xellia Pharmaceuticals. Primary endpoints: CDP-1 load in plasma and CDP-1-to-vancomycin ratio in infusion solution. Started Apr 2016; status: terminated.
02
Drugs
vancomycin
Beyond the preview
Go deeper on 2015-005349-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005349-29.